Remission has become one of the most used — and least defined — words in psoriasis care. A new discussion in HCPLive tackles the problem head-on: what does "on-treatment remission" actually mean for patients with psoriasis and psoriatic arthritis (PsA), and who gets to decide?

The question is not academic. Clinicians now have potent tools that can push disease activity to near zero. Yet without an agreed definition of remission while a patient stays on therapy, trials, registries and real-world clinics are measuring success differently. That gap makes it harder to compare drugs, taper therapy confidently, or tell a patient whether they are truly in remission or merely well controlled.

What is at stake in the definition?

In psoriasis, clearance is usually framed through PASI — the Psoriasis Area and Severity Index — with PASI 90 or PASI 100 as the benchmarks of deep response. In PsA, the conversation runs through composite measures that capture tender and swollen joints, skin, enthesitis and dactylitis.

The trouble is that "on-treatment remission" sits apart from both drug-free remission and low disease activity. A patient who holds PASI 100 while taking a biologic is not the same, biologically or economically, as one who sustains clearance after stopping. Conflating the two muddies both trial endpoints and shared decisions in clinic.

The takeaway: a fixed, consensus definition would let dermatologists and rheumatologists speak the same language about the same patient.

Why the two diseases complicate each other

Psoriasis and PsA share biology but not timelines. Skin can clear while joints smolder, and joint damage can progress while skin looks quiet. Any remission definition that leans only on visible plaques risks missing musculoskeletal disease, and one built purely on joint counts can miss nail and scalp involvement that matters deeply to patients.

That asymmetry is exactly why the HCPLive piece frames this as a cross-specialty problem. Dermatologists see the skin first. Rheumatologists see the joint first. A workable definition has to hold both in one frame, on treatment, over time.

The takeaway: remission must be judged across organs, not within a single specialty's field of view.

What comes next?

The path forward, as the discussion suggests, runs through formal consensus work: panels that weigh existing trial endpoints, registry data and patient-reported outcomes, then settle on thresholds clinicians can apply at the bedside. Until then, "remission" remains a word each clinic defines for itself.

For now, dermatologists would do well to ask patients on stable therapy a plain question — what does clear mean to you — and document the answer alongside the score.